Differential expressions of CD25 or CD71 on CD4+ and/or CD8+ tumor cells from a patient with adult T-cell leukemia/lymphoma: Three color flowcytometric analysis of peripheral blood and lymph node

1992 ◽  
Vol 40 (2) ◽  
pp. 160-161 ◽  
Author(s):  
Fumio Omata ◽  
Yukinobu Ichikawa ◽  
Yoshitaka Kushibiki ◽  
Hiroaki Shimizu ◽  
Miyoko Yoshida ◽  
...  
2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Yasuhisa Sando ◽  
Ken-ichi Matsuoka ◽  
Yuichi Sumii ◽  
Takumi Kondo ◽  
Shuntaro Ikegawa ◽  
...  

Abstract Photodynamic therapy (PDT) is an emerging treatment for various solid cancers. We recently reported that tumor cell lines and patient specimens from adult T cell leukemia/lymphoma (ATL) are susceptible to specific cell death by visible light exposure after a short-term culture with 5-aminolevulinic acid, indicating that extracorporeal photopheresis could eradicate hematological tumor cells circulating in peripheral blood. As a bridge from basic research to clinical trial of PDT for hematological malignancies, we here examined the efficacy of ALA-PDT on various lymphoid malignancies with circulating tumor cells in peripheral blood. We also examined the effects of ALA-PDT on tumor cells before and after conventional chemotherapy. With 16 primary blood samples from 13 patients, we demonstrated that PDT efficiently killed tumor cells without influencing normal lymphocytes in aggressive diseases such as acute ATL. Importantly, PDT could eradicate acute ATL cells remaining after standard chemotherapy or anti-CCR4 antibody, suggesting that PDT could work together with other conventional therapies in a complementary manner. The responses of PDT on indolent tumor cells were various but were clearly depending on accumulation of protoporphyrin IX, which indicates the possibility of biomarker-guided application of PDT. These findings provide important information for developing novel therapeutic strategy for hematological malignancies.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 3096-3096 ◽  
Author(s):  
Akira Umino ◽  
Masao Nakagawa ◽  
Atae Utsunomiya ◽  
Kunihiro Tsukasaki ◽  
Naoyuki Katayama ◽  
...  

Abstract Abstract 3096 Introduction: Adult T-cell leukemia/lymphoma (ATLL) is the neoplasia caused by Human T-cell leukemia virus type 1 (HTLV-1). HTLV-1-infected CD4+ T lymphocytes accumulate genetic and epigenetic changes during an extensive latency period, which can lead to neoplastic growth. Some studies have suggested that a rapidly growing clone in HTLV-1 provirus integrated T cells is selected, thus resulting in monoclonal expansion of more malignant tumor cells. In the present study, we analyzed ATLL samples using oligoarray comparative genomic hybridization (oligo-aCGH) and revealed the presence of multiple clones in the majority of ATLL patients investigated. Our data suggested that PTCL NOS is similar to ATLL with regard to polyclonal tumor cell expansion. Methods: We performed high-resolution oligo-aCGH (Agilent Technologies Santa Clara, CA, USA) containing a 44,000 probe set against 26 paired samples comprising peripheral blood and lymph node from 13 patients with acute type ATLL. Sixteen lymph node samples from PTCL NOS patients were also examined. Results: All of ATLL and PTCL NOS had genomic aberrations as determined by oligo-aCGH. 1) Polyclonality of ATLL oligo-aCGH analysis showed log2 ratio average imbalances among some chromosomes in 13 of the 26 ATLL samples. For example, in the case 1 lymph node sample (Figure 1), regions of gain were detected on chromosomes 2, 3, 7, 8 and 9 as shown by the log 2 ratio in parentheses: chromosome 2 (0.10), chromosomes 3 and 7 (0.41), chromosome 8 (0.25), and chromosome 9 (0.15). These results indicate that chromosome imbalance is present in one patient sample (Figure1). Importantly, in the case 1 peripheral blood sample, regions of gain were only detected on chromosomes 3, 7 and 8, with an associated log2 ratio of almost 0.53, suggesting the absence of no chromosome imbalance. These differential genomic aberration patterns between peripheral blood and lymph node samples were found in 9 out of 13 ATLL cases (Table 1). These cases strongly indicated that the majority of ATLL patients possess polyclonal tumors. 2) Clones were selected in the peripheral blood All cases examined had common genomic abnormalities between blood and lymph node samples from the same patient. However, cases 1, 2, 4, 8 and 12 indicated that selected clones from multiple clones of lymph node tumor cells had expanded in peripheral blood. A schematic representation of case 1 is shown in Figure 2. 3) Polyclonality of PTCL NOS Eight out of 12 PTCL NOS cases showed a log2 ratio imbalance, suggesting that similar polyclonal expansion is present in PTCL NOS. An evaluation of the four remaining cases was not possible since the log2 ratio imbalance was too low. Conclusions: Our results suggested that selected clones derived from a common origin may be present at the same time in acute type ATLL based on genomic analysis. The multi-clonal growth found in ATLL lymph node is also suggested to be present in PTCL NOS. Disclosures: No relevant conflicts of interest to declare.


1995 ◽  
Vol 48 (2) ◽  
pp. 116-119 ◽  
Author(s):  
Keisuke Shibata ◽  
Yoshinori Shimamoto ◽  
Kenji Suga ◽  
Masayuki Watanabe ◽  
Masako Kikuchi ◽  
...  

2003 ◽  
Vol 127 (5) ◽  
pp. 636-636
Author(s):  
Dragos C. Luca ◽  
Carey Z. August ◽  
Elliot Weisenberg

1992 ◽  
Vol 41 (4) ◽  
pp. 258-263 ◽  
Author(s):  
Naomichi Arima ◽  
Yasuhisa Daitoku ◽  
Shiroh Hidakia ◽  
Kakushi Matsushita ◽  
Hideo Ohtsubo ◽  
...  

Blood ◽  
2008 ◽  
Vol 112 (6) ◽  
pp. 2484-2488 ◽  
Author(s):  
Julie H. Lin ◽  
Ellen J. Kim ◽  
Anand Bansal ◽  
John Seykora ◽  
Stephen K. Richardson ◽  
...  

Abstract The oral rexinoid bexarotene (Targretin) is widely used for treatment of cutaneous T-cell lymphomas (CTCL). We recently reported the first case of adult T-cell leukemia/lymphoma (ATLL) that responded rapidly to combination therapy of bexarotene and interferon (IFN)-α2b with complete clinical response. We demonstrated that bexarotene induced apoptosis of the patient's malignant peripheral blood T-cells in vitro. However, our patient developed skin and nodal relapse 180 days after starting treatment. We now demonstrate that his peripheral blood malignant T cells became resistant to bexarotene-induced apoptosis. We investigated potential mechanisms that may cause aberrations in the retinoid X receptor (RXR) subunits, RXR-α and RXR-β, to account for these findings. Sequence analysis did not reveal acquisition of mutations in the genes encoding RXR-α and RXR-β by resistant cells. We assessed RXR-α and RXR-β expression by Western blot analysis and found that resistant cells had significantly decreased RXR-α expression compared with pretherapy bexarotene-sensitive cells. Our findings indicate that reduced expression of the RXR-α receptor subunit may represent a mechanism for resistance to bexarotene in T-cell malignancies.


2001 ◽  
Vol 105 (2) ◽  
pp. 103-105
Author(s):  
Hiroshi Fujiwara ◽  
Naomichi Arima ◽  
Tadashi Matsumoto ◽  
Hideo Ohtsubo ◽  
Kakushi Matsushita ◽  
...  

2019 ◽  
Vol 2019 ◽  
pp. 1-5 ◽  
Author(s):  
Satoko Kako ◽  
Satoru Joshita ◽  
Akemi Matsuo ◽  
Kenji Kawaguchi ◽  
Takeji Umemura ◽  
...  

We present the case of a 74-year-old Japanese woman who presented with dyspnea, a palpable right breast mass, and swollen right axillary lymph node. Imaging studies revealed bilateral pleural effusion and systemic lymph adenopathy and pleural fluid study showed high levels of triglycerides. A right inguinal lymph node biopsy disclosed malignant lymphoma cells that were human T-cell leukemia virus type 1 (HTLV-1) provirus DNA-positive, a condition endemic to patient’s birthplace, by the Southern blot hybridization method. She was diagnosed as having adult T-cell leukemia/lymphoma (ATL) with chylothorax. After commencing chemotherapy for ATL, her chylothorax disappeared and swollen lymph nodes reduced remarkably, indicating an association between the chylothorax and ATL. Bilateral chylothorax is a relatively rare condition associated with such nontraumatic causes as ATL. Clinicians should therefore bear chylothorax in mind when encountering patients with pleural effusion. A detailed medical history can also enable prompt diagnosis and appropriate treatment.


Oncogene ◽  
2020 ◽  
Vol 39 (35) ◽  
pp. 5782-5794
Author(s):  
Haruhito Totani ◽  
Keiko Shinjo ◽  
Miho Suzuki ◽  
Keisuke Katsushima ◽  
Shoko Mase ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document